DigestRedComo funciona
Red
/
Empresas
Ar
No verificado

Arrowhead Pharmaceuticals, Inc.

Sobre qué escribimos

BiotecnologíaCienciaFarmacéuticaMedicina - VariosSalud

70 Comunicados de prensa

Ver todos los comunicados de prensa
20/01/2026
Salud
Biotecnología
Medicina - Varios
Farmacéutica
Web y redes sociales
Telefonía
Finanzas
Mercado de valores
Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results
Fuente
Arrowhead Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
08/01/2026
Mercado de valores
Acciones y Obligaciones
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants
Fuente
Arrowhead Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
07/01/2026
Industria
Ciencia
Biotecnología
Farmacéutica
Salud
Higiene alimentaria
Medicina - Varios
Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China
Fuente
Arrowhead Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
06/01/2026
Salud
Farmacéutica
Finanzas
Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock
Fuente
Arrowhead Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
06/01/2026
Ciencia
Cardiología
Biotecnología
Farmacéutica
Salud
Medicina - Varios
Web y redes sociales
Industria
Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition
Fuente
Arrowhead Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
05/01/2026
Industria
Salud
Biotecnología
Farmacéutica
Medicina - Varios
Sanidad
Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
Fuente
Arrowhead Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
23/12/2025
Eventos
Ferias y Congresos
Ciencia
Biotecnología
Farmacéutica
Sanidad
Salud
Medicina - Varios
Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events
Fuente
Arrowhead Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
15/12/2025
Mercado de valores
Ciencia
VIH, SIDA y enfermedades autoinmunes
Biotecnología
Medicina - Varios
Biología
Sanidad
Farmacéutica
Salud
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Fuente
Arrowhead Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
08/12/2025
Industria
Ciencia
Biotecnología
Farmacéutica
Salud
Medicina - Varios
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies
Fuente
Arrowhead Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
02/12/2025
Industria
Higiene alimentaria
Salud
Ciencia
Farmacéutica
Biotecnología
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia
Fuente
Arrowhead Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0